Maintenance therapy in non-small-cell lung cancer (Q43274033)

18 November 2017

Maintenance therapy in non-small-cell lung cancer (English)

1 reference

18 November 2017

Thomas E Stinchcombe

1

1 reference

PubMed ID

19767096

18 November 2017

Howard L West

series ordinal

2

1 reference

PubMed ID

19767096

18 November 2017

language of work or name

English

0 references

publication date

18 September 2009

1 reference

18 November 2017

1 reference

18 November 2017

374

1 reference

18 November 2017

9699

1 reference

18 November 2017

1398-1400

1 reference

Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

18 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961598-1

7 January 2021

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961598-1

7 January 2021

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961598-1

7 January 2021

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961598-1

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961598-1

7 January 2021

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961598-1

7 January 2021

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961598-1

7 January 2021

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961598-1

7 January 2021

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961598-1

7 January 2021

10.1016/S0140-6736(09)61598-1

Identifiers

DOI

1 reference

18 November 2017

1 reference

PubMed ID

19767096